Henry Schein (NASDAQ:HSIC – Get Free Report) had its price target upped by equities researchers at Jefferies Financial Group ...
Jefferies analyst Glen Santangelo assigned a Hold rating to Henry Schein (HSIC – Research Report) today and set a price target of $80.00. The ...
Jefferies raised the firm’s price target on Henry Schein (HSIC) to $80 from $77 and keeps a Hold rating on the shares. Management has a strong ...
Activist investor Ananym Capital Management plans to nominate as many as half a dozen directors to the board at Henry Schein, ...
Ananym Capital Management, an activist investor, has plans to nominate up to six directors to the board of Henry Schein ...
Activist investor Ananym Capital Management to nominate directors to Henry Schein board, pushing for CEO change and cost ...
Tuesday was the Ohio Valley Health Center’s first day providing an in-house echocardiogram for one of its patients, through a ...
This was the stock's third consecutive day of gains.
Henry Schein, Inc. (HSIC) stock saw a modest uptick, ending the day at $73.22 which represents a slight increase of $1.47 or 2.05% from the prior close of $71.75. The stock opened at $72.23 and ...
With the game of the season just days away, WIVB News 4 Sports Director Josh Reed recently spoke with SiriusXM’s Adam Schein ...
Adam Schein of Mad Dog Sports Radio thinks things have gotten stale in Pittsburgh with Mike Tomlin as head coach, ...
Tampa, Florida-based Acentus, a national medical supplier, specializes in the delivery of continuous glucose monitors (CGMs).